Pharmacy Drugs
Recent Posts
- EPIX Pharmaceuticals Announces FDA Approval Of A Physician-Sponsored IND For Fourth 6-month Open Label Extension Of PRX-03140 For Alzheimer’s Disease
- Miriam Hospital Researcher Receives More Than $12 Million To Study Weight Control
- Novel HIV Drug To Be Studied In Cell Cultures And Patients
- ISCTM Meeting Discusses Clinical And Regulatory Aspects Of Using Adaptive Designs In Clinical Trials For Central Nervous System Drug Approvals
- Evaluation Of The Cost Effectiveness Of Implantable Blood Pressure Device
Random Posts
- The Way To Overcome Emotional Disturbances In Children May Be Improving Their Psychological Well-being
- Phase I Study Of Preventive HIV Vaccine Shows Improved Immune Responses When The Vaccine Is Delivered By Electrical Impulses
- Study Aims To Induce Recovery From Ankylosing Spondylitis
- Pharmaceutical Company Manager Sentenced For Off-Label Marketing
- New Survey Shows Substantial Growth And Some Challenges With Electronic Data Capture In Clinical Trials
- Potential New Drugs: 970 Million And Still Counting - Journal Of The American Chemical Society
- The Countdown Starts For Pharmacy Technician Registration
- Interim Results Of Abbott's PROGRESS Study Show Rapid Viral Decline In Dual-Therapy Regimen Of Kaletra(R) (lopinavir/ritonavir) And Raltegravir
- Familial Alzheimer Disease Network Enrolling, Making First Move Toward Clinical Trials
- Cardiovascular Systems Announces First Patient Enrolled In COMPLIANCE 360 Degree Clinical Trial
NeoChord Enrolls First Patient In European Clinical Trial
Posted by: admin in Pharmacy Drugs on November 15th, 2009
NeoChord, Inc., a venture-backed, Minneapolis-based medical technology company, announced today that it has enrolled the first patient in its European clinical trial. The trial, known as TACT (transapical artificial chordae tendineae) is being conducted in Germany, Denmark, Czech Republic and Norway.
“We are very pleased with the early results of this first procedure,” said Per Wierup and Sten Lyager Nielsen, the cardiac surgeons who performed the surgery. “The patient is an otherwise healthy, very active 47-year-old male who preferred to not have a sternotomy or cardiopulmonary bypass to fix his severe mitral regurgitation. The NeoChord approach has successfully treated his mitral regurgitation and potentially offers him a quick return to his military career and favorite hobby, scuba diving.”
Intra-operative transesophageal echocardiography (TEE) confirmed that the patient’s severe, eccentric mitral regurgitation was reduced to zero or trace mitral regurgitation. Giovanni Speziali, MD, the cardiac surgeon who is the primary inventor of the NeoChord device also attended the procedure. “These results, although early, are equivalent to what we obtain in traditional open heart surgery for correction of mitral regurgitation,” said Dr. Speziali.
The NeoChord procedure was developed to treat sub-valvular chordal damage - the primary cause of degenerative mitral regurgitation - via minimally invasive implantation of artificial chordae tendineae. The technology was developed by Speziali and other doctors at the Mayo Clinic and exclusively licensed to NeoChord.
“We’re very pleased to have achieved the first-in-man milestone and want to extend our very best wishes to the patient and his family,” said John Seaberg, CEO of NeoChord. “This successful outcome is the result of several years of hard work by our product development staff and our clinical advisors. I’m extremely proud of the extended NeoChord team.”
About Degenerative Mitral Regurgitation (DMR)
DMR occurs when the leaflets of the heart’s mitral valve do not close properly, usually due to rupture or elongation of the chordae tendineae (chords) that control the leaflet’s motion. During pumping, the “leak” in the mitral valve causes blood to flow backwards (mitral regurgitation) into the left atrium, thereby decreasing blood flow to the body. Mitral regurgitation is a progressive disease that left untreated can result in heart failure, and death.
Source
NeoChord, Inc.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.